agm report

Hi all,

this is just a quick post with a few impressions of the agm, I still have to digest it all and read the official versions as published in the announcements that came out at the same time.

I have to admit it was slightly weird watching the price spike to 7.4 just as Treagus started talking.

There were about 14 people there including the Bell Potter bloke and a few "regulars" (well they were there last year).

Larry Glass' nifty marketing line for 2256 was "aspirin for the brain". The dream is that it will prove to be effective in treating a bunch of autism related illnesses, obviously Retts ($1.3b potential per year) and Fragile X ($5b potential per year). But, speculatively, it may play a role in reducing brain ageing effects and you could imagine a scenario where old people take it preventatively. Again: that's the dream.

LG made the point that he views the effect of 2256 on the rodent models as really outstanding (obvious caveat: they're rodents not people) and also emphasised that they used "real world" equivalent doses.

2291 is being seen at this stage as a "backup" with long term plans targeting more the degenerative market like Parkinsons.

The talk was really all about 2256. 2291 got a brief mention and the other stuff barely a look in.

I asked LG a few questions which filled in some gaps for me:

If the EFIC trial expands the number of hospitals to the hoped for 18, they would ideally get about 20 recruits a month,.

The Perseis results due third quarter this year should put them roughly where they wanted to be in May last year, arguably better as they have 5 lines not 2.

The Retts trials are non trivial. They only run with a handful of patients at a time because the evaluation requires substantial outpatient services. So it's not as simple as giving 60 people a bunch of tablets and getting them to come back in a month.

Anyway, very interesting, I really have to read the official transcripts to see what I've missed saying.